Kamyar Farahi

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Subrata Ghosh, Lianne S. Gensler, Zijiang Yang et al. · Drug Safety · 2019 · 114 citations · Full text

A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

David M. Pariser, Brad Schenkel, Chureen Carter et al. · Journal of Dermatological Treatment · 2015 · 92 citations · Full text

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial

Michael A. Loesche, Kamyar Farahi, Kimberly Capone et al. · Journal of Investigative Dermatology · 2018 · 67 citations

Inflammation, Psoriasis-associated Skin Microbiome, Medicine +7

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)

Andrew Blauvelt, Laura K. Ferris, Paul S. Yamauchi et al. · British Journal of Dermatology · 2017 · 61 citations · Full text

Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis

Mingliang Zhang, Susan K. Brenneman, Chureen Carter et al. · Patient Preference and Adherence · 2015 · 32 citations · Full text